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Introduction: Natural killer (NK) cells are key components of the innate immune system 
and participate in the early response against infected or transformed cells. They are 
characterized by the expression of a varied repertoire of receptors, named inhibitors 
and activators, which balance mediates their function. NK cell contribution in infection 
remains unclear. Mycobacterium tuberculosis infection is still a significant health 
problem and it will probably become even more significant in coming years because of 
the high prevalence of human immunodeficiency virus (HIV). The main goal is to clarify 
the role of NK cells in immunopathogenesis and hypothetical contribution as targets for 
therapy interventions. 
Material and methods: Peripheral blood from 38 TB patients and 15 HC was analysed. 
Complete Blood Cells count as well as enumeration of lymphocyte subsets was made. 
NK cell surface expression of some important receptors and markers (CD56/CD16, 
CD27/CD11b, CD57, CD94/NKG2D, NKp30, NKp44, NKp46, NKp80, KIR2DL1, 
KIR2DL2, KIR3DL1, KIR2DS1) were evaluated and also the intracellular expression of 
IFN-γ. 
Results and Discussion: A moderate lymphopenia was observed in TB patients, with a 
decrease of all lymphocyte subsets, except for B cells. NK cells from TB patients 
present a higher level of maturation and IFN-γ production. The most marked increase 
in surface markers expression was observed for CD57. 
Conclusion: The general NK cells phenotyping here presented can help in the 
understanding of NK cell role in pulmonary tuberculosis infection and progression to 
disease, giving some highlights for further research.  
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Introdução: As células Natural Killer (NK) são componentes chave do sistema imune 
inato e participam numa primeira fase da resposta contra células infectadas ou 
danificadas. São caracterizadas pela expressão de um variado repertório de 
receptores, incluindo inibidores e activadores, cujo balanço irá mediar as funções 
destas células. A contribuição das células NK na infecção não se encontra definida. A 
infecção pelo Mycobacterium tuberculosis continua a ser um grave problema de saúde 
pública, podendo vir-se a agravar devido ao aumento da prevalência da infecção com 
o vírus da imunodeficiência humana (HIV). O principal objectivo deste trabalho foi 
clarificar o papel das células NK na imunopatogénese desta doença e a sua hipotética 
contribuição como alvos terapêuticos. 
Material e Métodos: Neste estudo foram analisadas amostras de sangue periférico de 
38 doentes com tuberculose e 15 contactos saudáveis. Foi feito um hemograma 
seguido da enumeração dos subtipos dos linfócitos presentes. A expressão na 
superfície das células NK de alguns receptores e marcadores importantes 
(CD56/CD16, CD27/CD11b, CD57, CD94/NKG2D, NKp30, NKp44, NKp46, NKp80, 
KIR2DL1, KIR2DL2, KIR3DL1, KIR2DS1) foi avaliada juntamente com a expressão 
intracelular de IFN-γ. 
Resultados e discussão: Foi observada uma linfopenia moderada nos doentes com 
tuberculose, com um decréscimo em todos os subtipos de linfócitos, à excepção das 
células B. As células NK dos doentes com tuberculose apresentaram níveis mais 
elevados de maturação e de produção de IFN-γ. O aumento mais acentuado registou-
se na expressão do CD57. 
Conclusão: Os dados aqui apresentados relativos à fenotipagem das células NK 
poderão ajudar na compreensão do papel destas células na infecção pela 
Mycobacterium tuberculosis e progressão para doença, abrindo perfectivas de 
utilização das células NK como alvos terapêuticos.  
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Immune System 
 The immune system is a specialized network of organs, cells and soluble 
mediators that all together forms a defence mechanism against invading pathogens, 
infectious agents and transformed cells. The immune system can be divided into two 
branches: the innate and the adaptive systems. Both systems interact and complement 
each other to provide the protection of the body. 
 Innate immune system 
 The innate immune system offers a first barrier against penetration and is 
quickly activated after tissue injure or infection and targets pathogens non-specifically. 
However, it does not have memory, so the immune response will not increase with next 
exposure to the same pathogen. Physical barriers (skin and mucosal membranes), 
which prevent the infection by a pathogen, are combined with a set of cellular 
mechanisms and soluble factors that are able to destroy a pathogen once the infection 
occurred. 
 The most important cells in a response to an infection are phagocytic white 
blood cells like macrophages and neutrophils, competent to ingest and kill microbes by 
producing toxic chemicals and degradative enzymes, and Natural Killer (NK) cells, 
which mediate lysis of target cells. During the early phase of the innate immune 
response, both cell types produce cytokines, which cause a local inflammation and 
active the adaptive immune system. NK cells are crucial for early defence against 
infections and tumour surveillance and also represent a connecting cell type between 
innate and adaptive immune system. 
 As phagocytic cells, macrophages and neutrophils are important in the 
elimination of pathogens. Macrophages migrate to the site of infection after neutrophils 
but are also involved in other functions, such as initiating healing and stimulating the 
adaptive immune response. Like macrophages, dendritic cells serve as antigen-
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presenting cells (APCs) and stimulate the adaptive response. On the other hand, 
natural killer cells are quickly activated lymphocytes that attack tumours and cells 
infected with virus.  
 In order to be alerted, the innate immune system displays a set of receptors, 
which recognize many related molecular structures called pathogen-associated 
patterns (PAMPs). PAMPs are molecular motifs consistently found on pathogens and 
not in the host. They are recognized by toll-like receptors (TLRs) and other pattern 
recognition receptors (PRRs), such as dectins and nucleotide-binding oligomerization 
domain containing (NOD). The binding of PAMP to cells of the innate immune system 
results in killing of the pathogens and secretion of pro-inflammatory cytokines. The 
innate immune system acts within minutes to hours after an infection and many of the 
effector and costimulatory molecules generated during this early phase of the immune 
response play an important role for the slower developing adaptive response. 
 Adaptive immune system 
 Although 90% of infections are eliminated by mechanisms of the innate immune 
system, some pathogens escape the defences and the adaptive immune system has to 
be activated. Soluble factors that belong to the complement system and chemokines 
and cytokines secreted by innate immune system induce recruitment of lymphocytes 
and the activation of the adaptive immune system. Adaptive immunity is mainly exerted 
by two types of lymphocytes, namely T cells and B cells. In contrast to innate immune 
cells, T and B lymphocytes express antigen specific receptors (TCR and BCR, 
respectively) which undergo genetic recombination in somatic cells. This process 
provides with a highly diverse repertoire of receptors able to recognize plenty different 
pathogen-derived antigens. Adaptive immunity not only contributes to pathogen 
clearance but is also essential for the formation of an immunological memory allowing 
fast acting responses in case of reinfection. The protection of the extracellular fluids 
and spaces is mediated by humoral immune response, in which antibodies produced 
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by B cells bind to extracellular pathogens and toxins. Activation of naive B cells is 
triggered by binding of the BCR to its specific antigen and usually requires the help of T 
cells. Following antigen binding to the BCR, B cells become activated and differentiate 
into antibody secreting plasma cells. The secreted antibodies bind specifically to the 
antigen on the pathogen surface, subsequently leading to complement activation and 
phagocytosis of the pathogen. Also NK cells recognize target cells coated with 
antibodies, leading to lysis of the target cell by so-called antibody dependent cellular 
cytotoxicity (ADCC). 
 Different from B cells, T cells are not able to recognize the pathogens directly, 
needing the help of a professional APC which have been activated by pathogen-
derived PAMP degrade the pathogen and present the antigens on major 
histocompatibility complex (MHC) molecules expressed on their surface leading to T 
cell activation and clonal expansion. Among T cells, two populations can be 
distinguished: CD4+ T helper (TH) and CD8
+ cytotoxic T cells. CD8+ T cell activation 
and release of cytotoxic molecules leads to killing of the infected target cells and CD4+ 
T cell do not only stimulate innate cells but also play a crucial role in activating other 
adaptive cells, contributing to the elimination of the pathogen. 
 Summing up, innate and adaptive immune responses intensively cooperate with 
each other contributing to pathogen elimination. While the innate immune system has a 
crucial importance during the early phase of a primary infection but does not provide 
immunological memory, the adaptive system takes longer to be activated but have 
immunological memory, which allows an even quicker response in case of re-exposure 
to the same pathogen. (1, 2) 
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Natural Killer Cells 
Natural killer (NK) cells represent the third largest lymphoid cell population in 
mammals, are key components of the innate immune system and participate in the 
early response against infected or transformed cells (3). They constitute a first line of 
defence and can kill infected and tumor cells.  These cells are large, granular, bone-
marrow – as well as lymph node-derived lymphocytes. However, NK cells are distinct 
from T cells or B cells and have distinct morphologic, phenotypic and functional 
properties. NK cells do not require sensitization for the exertion of their activity 
differently from T cells or B cells (4).  
NK cells are present in blood as circulating cells and to other organs of the body 
as resident cells. In peripheral blood, they are characteristically described as having 
the morphology of large granular lymphocytes (5), whereas in tissues, the 
microenvironment of the organ has influence on phenotype and activity of NK cells. 
They are characterized by the expression, on their cell surface, of a varied repertoire of 
receptors, named inhibitors and activators, which balance mediates their function (6). 
The balance of inhibitory and stimulatory signals received by a NK cell determines the 
outcome of interactions with target cells. Normal target cells are protected from killing 
by NK cells when inhibitory signals delivered by self MHC class I molecules 
compensate the signals delivered by stimulatory ligands (7). 
 Development and maturation 
NK cells are believed to be relatively short-lived lymphocytes. They derived 
from CD34+ hematopoietic progenitor cells (HPC) and some observations indicate that 
the bone marrow (BM) and lymph nodes (LN) are important for their 
development/maturation (8, 9). 
Primarily, NK cell development occurs in the BM, and despite the critical factors 
necessary for development are still unknown, some analyses demonstrated the 
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presence of an enriched microenvironment with CD34+ HPC, including a fraction of NK 
cell precursors (pre-NK) in BM(10). IL-2 has been used to study NK cell development 
from CD34+ HPC in vitro (10-12), however, this cytokine is not found within the BM 
stroma (11, 13, 14), so other factors that bind to the IL-2R are critical for NK cell 
development. IL-15 is produced by human BM stromal cells and its function have 
demonstrated to facilitated the differentiation of cytolytic NK cells from CD34+ HPC (15) 
because this cytokine shares common signalling receptor subunits with IL-2, which 
form an intermediate-affinity heterodimeric receptor complex, IL-2/IL-15Rβγ (16). It has 
been demonstrated that only the CD34+ CD45RA+ phenotype is all-inclusive for human 
IL-2/IL-15-responsive pre-NK cells (17, 18). Other BM stromal cell factors such as c-kit 
ligand (KL) and flt3 ligand (FL), the ligands for members of the class III receptor 
tyrosine kinase family (includes c-kit and flt3), have been shown to potentiate 
significantly the expansion of NK cells from CD34+ HPC in combination with IL-15, 
however alone these molecules have no effect on cell differentiation into NK cell (19, 
20). In development, NK cell it may be divided into an early phase in which FL acts 
synergistically with IL-15 to generate an exclusive CD34+CD122+CD38+ NK cell 
intermediate subset from CD34+ HPC, and where IL-15 is necessary to increase the 
mature NK cells characteristics such as CD56 and NKR expression, cytotoxic activity 
and the ability to produce abundant cytokines and chemokines (11). CD56 is a 140-
kDa isoform of neural cell adhesion molecule (NCAM). 
LN are also naturally and selectively enriched with CD34dimCD45RA+ HPC and 
are able to differentiate these cells into CD56bright NK cells in the presence of either IL-2 
or IL-15 (17).  Fehniger et al. (21) showed that endogenous T cell-derived IL-2 may 
trigger, through the NK high-affinity IL-2 receptor, CD56bright NK cells to produce IFN-γ. 
This selective enrichment of both CD34dimCD45RA+ HPC and CD56bright NK cells within 
LN compared with the BM or blood is suggesting of LN as a site for NK cell 
development.  
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There are two distinct blood subsets of human NK cells identified by cell surface 
density of CD56 (22). NK cells in human peripheral blood are majority CD56dim, express 
high levels of CD16 and killer cell immunoglobulin-like receptor (KIR) and a minority 
are CD56bright CD16dim/neg, having low cytotoxic activity and secrete more cytokines in 
response to stimulation (22).  Furthermore, Romagnani et al. (23) demonstrated that 
CD56dim NK cells from peripheral blood exhibit shorter telomeres than peripheral and 
LN-derived CD56bright NK cells. 
The NK cell development stages in human are not yet well established but 
based on the presence of different expression kinetics of surface markers could define 
distinct stages of their development. Freud et al. (24)  based on the principle that: more 
than 99% of NK cells within LN express at least CD34, CD117, and/or CD94;  CD34 
and CD94 are independent antigens, indicating that NK cells intermediate stages would 
first lose CD34 and then express CD94; and NK cell functional maturity (cytotoxic and 
IFN-γ secretion) as well as acquisition of surface CD56 in humans are acquired at a 
later stage of development (25, 26), have proposed a marker panel set using the 
combination of CD34, CD117, CD94 and CD16 to differentiate the functionally distinct 
stages of human NK cell development (figure 1).  
The first stages of NK cells differentiation are dependent of concomitant IL-15 
responsiveness and not all CD34+ CD117+ CD94- cells are compromised with NK cell 
lineage. Immature NK cells (iNK cells), are different from the first developmental stage 
of NK cell because these cells are completely incapable to generate T cells and DC, 
being this way committed with NK cell lineage (8, 24). iNK cells express antigens 
including CD2, CD7, CD56, CD161 and NKp44, besides lack of CD10, integrin β7 and 
HLA-DR, characteristics that further will distinguish the iNK cells phenotype from pre-
NK cells. In this third developmental stage, iNK cells are  exclusively in NK cell branch 
however they are not capable to produce IFN-γ or mediate perforin-dependent cellular 
cytotoxicity against MHC-I negative target cells (24). CD56+ cells can express different 
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levels of CD117 and are subdivided in CD56+CD117high and CD56+ CD117low/- subsets 
(27). These populations are considered different since the latter expresses NKp30, 
NKp46, NKG2D, NKG2A and CD94, while CD56+CD117high cell do not. It were been 
shown that CD56+CD117highCD94- cells are not cytotoxic and CD56+CD117low/-CD94+ 
effectively kill target cells and express high levels of FasL and IFN-γ, representing 
differentiation at stage 4. KIR+ NK cells are primarily within the CD56dimCD94+/-CD16+ 
fraction of cells in both LN and peripheral blood, whereas the CD56bright CD94+CD16+/-
do not express KIR, which is consistent with evidence indicating that KIR acquisition is 
rather a late event during NK cell maturation (28-30).  
Stage 1 
(Pro-NK) 
Stage 2 
(Pre-NK) 
Stage 3 
(iNK) 
Stage 4 
(CD56
bright
) 
Stage 5 
(CD56
dim
) 
CD34
+
 CD34
+
 CD34
-
 CD34
-
 CD34- 
CD117
-
 CD117
+
 CD117
+
 CD117
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 CD117
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-
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-
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+
 CD94
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-
 CD16
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 CD16
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+
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  NK cell maturation 
    Cytotoxicity 
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Figure 1 – Phenotypic features used to discriminate the main NK cell subsets during the ontogenic 
process. This figure brings the more important markers acquired during the five ontogenic stages (31) 
 
The dominant NK cell subset in LN are CD56bright (75% median value), however, 
in peripheral blood and spleen, the majority of NK cells are a more mature subset: 
CD56dim (95% and 85%, respectively) (32). Moreover, the CD56dim subsets in the 
spleen and in the peripheral blood express CD16; CD56bright NK cells in LN are 
negative for CD16 and express low levels of activation markers (HLA-DR and CD69) 
(32). These observations suggest that the CD56bright cells are more immature and will 
give rise to CD56dimCD16+ NK cells (the last stage of NK cell life) inside the LN and 
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then go to peripheral blood. It is important to mention that despite these stages 
representing a possible developmental NK cell pathway, it is still possible that some 
cells from each stage may still be terminally differentiated with essential functions for 
body homeostasis. 
 
Figure 2 – Phenotypical and functional properties of CD56
bright
 and CD56
dim
 NK cells. (a) Schematic 
illustration of CD56 and CD16 expression on CD3
-
CD4
-
CD14
-
CD19
-
 lymphocytes with gates on CD56
bright 
(blue) and CD56
dim
 (red) NK cells. (b) Relative expression levels of activation and inhibitory receptors on 
CD56
bright
 (blue) and CD56
dim
 (red), and NK cells from peripheral blood. (c) Functions of CD56
bright
 and 
CD56
dim
 NK cells from peripheral blood (adapted from Björkström et al. Trends Immunol 2010 (33))  
 
Fu et al. (34) recently found that according to the differential CD27/CD11b 
expression NK cells could be characterized in terms of maturation state. This work 
refer that during NK cell maturation, they acquire CD27 having a highest cytokine 
expression, suggesting that NK cells had the ability to produce cytokines, low 
expression of CD16, suggesting a diminished cytotoxic capacity. After acquisition of 
CD27, NK cells acquire CD11b and lost CD27. These NK cells had the highest CD16 
expression, suggesting that they have the strongest cytotoxic capacity. Summary, NK 
cells during development/maturation pass for four stages according to CD27/CD11b 
expression: CD27-CD11b-, CD27+CD11b-, CD27+CD11b+ and finally CD27-CD11b+. 
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Recently, CD57 was described as a marker for NK cell terminal differentiation 
as happens in CD8+ T cells (35). Authors refer CD57+ NK cells as subset of highly 
mature cells, having lower frequency of IFN-γ+ cells comparatively to CD57- cells, lower 
proliferative capacity and with a mature phenotype. 
 Function properties 
NK cell functions can be classified in three categories: cytotoxicity, cytokine and 
chemokine secretion and contact-dependent cell costimulation. 
Cytotoxicity 
NK cells can kill certain infected cells and tumor target cells apart of their MHC 
expression (36). NK cells have a relatively large number of cytolytic granules (secretory 
lysosomes) containing perforin and various granzymes. After the contact between an 
NK cell and its target, these granules travel to the contact zone with the susceptible 
target cell (immunological synapse), and the contents are released to effect lysis. 
Perforin-dependent cytotoxicity is the major mechanism of NK cell lysis, but NK cells 
have also other ways of killing, namely in a perforin-independent manner utilizing FAS 
ligand, TNF or TNF-related apoptosis-inducing ligand (TRAIL), although with less 
efficiency and in a slower time kinetic.  
Cytokine and chemokine secretion 
NK cells are best noted for their ability to produce IFN-γ but also produce a 
number of other cytokines and chemokines which contribute to the resistance against 
infectious agents (37-39). Killing and cytokine secretion are mediated by two different 
subsets of human NK cells characterized by the intensity of expression of CD56 and 
CD16 on their surface. 
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Contact-dependent cell costimulation 
NK cells express several costimulatory ligands including CD40L (CD154) and 
OX40L, allowing them to provide a costimulatory signal to T cells or B cells (40, 41). 
NK cells may serve as a bridge in an interactive loop between innate and adaptive 
immunity. Dendritic cells (DC) stimulate NK cells, which then deliver a costimulatory 
signal to T or B cells allowing for an optimal immune response. NK cells also stimulate 
cells from the innate immune systems after being stimulated by them. 
 Cytokines and chemokines 
The cytokines play a key role in NK cell activation. They are immunomodulating 
molecules, once secreted by infected cells, they signal NK cells for the presence of 
pathogens. NK cells produce cytokines after being stimulated, in part by the monocyte-
derived cytokines during the early pro-inflammatory response to infection and also by 
the a subset of NK cells present at the site of inflammation (42). 
NK cells produce a range of cytokines, including haematopoietic factors such as 
IL-3 and granulocyte–macrophage colony-stimulating factor (GM-CSF), TNF-α and 
regulatory cytokines such as transforming growth factor (TGF-β) and IFN-γ (42). In both 
viral and bacterial models of infection, IFN-γ production by NK cells has been shown to 
be a crucial event in successful resolution of infection (43). These molecules secreted 
by NK cells will stimulate phagocytosis of bacteria by macrophages and facilitate their 
elimination via a number of mechanisms including the generation of reactive oxygen 
and nitrogen species important in immune response (44). In a very early phase of 
infection, IL-12 is produced and will be responsible for driving NK cells to produce IFN-
γ (45).  
The CD56bright NK cell subset produces significantly more IFN-γ following IL-18 
and IL-12 stimulation compared with CD56dim NK cells (45).  
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 Natural Cytotoxicity Receptors (NCRs) and other activating receptors 
Natural cytotoxicity receptors are an important group of activating receptors 
consisting of NKp30 (CD337), NKp44 (CD336) and NKp46 (CD335) expressed 
exclusively on NK cell surface (46). NCRs play a major role in the NK-mediated killing 
of most tumor cells (47). NKp46 and NKp30 are constitutively expressed on resting or 
activated NK cells, enabling a precise identification of all NK cells (which is not true for 
other widely used NK cell markers including CD56 and CD16) and NKp44 is selectively 
expressed only by IL-2 activated NK cells (47, 48). The ligands for the NCRs are not 
well characterized but seem to exist on tumor cells and virally infected cells. 
NK cells also express other triggering receptors that contribute to cell activation 
and target cell killing, including NKG2D, NKp80, NTB-A (CD352), 2B4 (CD244), 
DNAM-1 (CD226), and NKG2C. Among these molecules, NKG2D forms homodimers, 
is not structurally related to the other NKG2 receptors and represents a major triggering 
receptor that is known to specifically recognize the stress-inducible MHC class I-related 
chain molecules and plays a role in NK-mediated cytolysis (47, 49). On the contrary, 
NKp80, NTB-A, 2B4, and NKG2C appear to synergize with NCRs and NKG2D in the 
NK-mediated cytolysis, working as co-receptors (47).  
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Figure 3 – Activating NK receptors and coreceptors and their cellular ligands. This figure illustrates the 
molecular structure of the NK receptors NKp46, NKp30, NKp44 and NKG2D as well as of the NK 
coreceptors 2B4, NTB-A, DNAM-1 and NKp80. Their interaction with signaling polypeptides or with 
relevant cytoplasmic molecules is also shown. The known cellular ligands are illustrated in a simplified 
form. (Moretta et al. EMBO J 2004 (46)) 
 
 Cross-talk with other immune cells 
NK cells  have a regulatory action that influence various other immune cell 
types, such as macrophages, DCs, T cells and B cells. NK cells can interact with DCs 
in peripheral tissues, as well as in secondary lymphoid organs, and can have two 
distinct ways of action (50-52). First, NK cells are capable to kill immature DC, 
influencing DC homeostasis, but they can also limit DC-based vaccination efficiency 
(53, 54). However, the lysis of target cells by NK cells can cause cross-presentation of 
antigens from apoptotic NK cell targets by some DCs’ subsets. This mediated 
cytotoxicity exerted by NK cell on target cells induces robust antigen-specific adaptive 
immune responses that involve CD8+ T cells, CD4+ T cells and immunoglobulin G (55). 
Second, by the secretion of IFN-γ and tumor necrosis factor (TNF), NK cells can help 
the development of DCs, which will also activate NK cells by secretion of IL-12 (50-52). 
This interaction between NK cells and DCs might thus lead to anti-inflammatory 
applications.  
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In addition to the influence exercised in DC function, NK cells also influence 
adaptive immune responses by direct action on T and B cells. The IFN-γ secretion by 
NK cells can help the priming of CD4+ T helper type 1 (TH1) (56, 57). NK cells have 
also the capacity of killing activated T cells, except T cells express sufficient amounts 
of classical or non-classical MHC I molecules (58). Blockade of CD94-NKG2A 
inhibitory receptors results in NK cell lysis of activated CD4+ T cells. This knowledge 
can be useful in CD4+ T cell-dependent autoimmunity therapy by the use of  blocking 
antibodies to NKG2A to prevent it (58).  
NK cells not only protect the host against pathological agents, but also control 
the immune response exerted by other immune cells. 
 Killer-cell Immunoglobulin-like Receptors (KIRs) 
Natural Killer cells and some subsets of T cells express in its surface receptors 
belonging to the immunoglobulin-like receptors (KIRs).  KIR nomenclature is based on 
its structure: they can have two (KIR2D) or three (KIR3D) extracellular immunoglobulin-
like domains (59, 60). The cytoplasmic tail varies in length, a property connected to 
functional activity: inhibitory KIRs have long (L) cytoplasmic tails with ITIM motifs and 
activating KIRs have short (S) cytoplasmic tails which can associate with the ITAM-
containing DAP12 adaptor protein.  
Currently, about 14 KIR genes and 2 pseudogenes have been described in the 
KIR gene cluster on chromosome 19 in humans. The number of genes varies greatly 
between individuals and there are only three commonly shared framework genes 
present in all individuals (KIR2DL4, KIR3DL2 and KIR3DL3). KIR genes are highly 
homologous so it is likely that the variability is due to gene duplications or non-allelic 
homologous recombinations during evolution (61).  
Based on the gene content two types of haplotypes have been defined, where B 
haplotypes have more activating KIRs compared to A haplotypes. KIR haplotype B 
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have one or more of the KIR genes; 2DS1, 2DS2, 2DS3, 2DS5, 3DS1 and 2DL5 and 
haplotype A lack all of these and can as an alternative possess inhibitory KIRs 
including 2DL1, 2DL3 and 3DL1 as well as the activating 2DS4 (62). An extensive 
allelic variation in several genes confers an even higher diversity to KIR genes that will 
influence the amount of KIR expressed on each NK cell (63-65). In addition, some 
allelic variants do not produce functional proteins expressed at the cell surface (64).  
This highly diverse expression is believed to be important for giving a broad NK cell 
response against different pathogens.  
The KIR proteins are also expressed in a diverse way on NK cells (59, 60, 66). 
However, once an NK cell clone has started to express a certain KIR gene during 
development, the expression is established and does not appear to be affected by 
cytokines (64, 67). In recent studies, it was described that KIR gene transcription is 
controlled by epigenetic mechanisms such as methylation, and by the presence of a 
bidirectional promoter able to stochastically switch direction of transcription during 
maturation of the NK cell, determining if the NK cell will express the KIR gene or not 
(68, 69). Resulting in a diverse KIR expression repertoire in NK cells that can recognize 
almost every MHC class I molecule (66). 
 
Natural Killer cells in infection 
NK cells have long been demonstrated to be activated in vitro by virus-infected 
cells (70). Other types of intracellular pathogens have also been shown to activate NK 
cells for IFN-γ production or increase cytotoxicity (70, 71). Evidence for an implication 
of NK cells in the control of extracellular pathogens is not defined (72).  
NK cells are activated by a variety of intracellular pathogens, including many 
viruses and also bacteria or protozoa having potential to contribute to the immune 
defence against a variety of infections. However, in certain infections were a high of NK 
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cell activation is observed, there is no evidence that NK cells play a direct role in the 
control of the pathogen (73). Thus, the modulation of NK cell functions by an infection 
is not enough to indicate that NK cells contribute directly to the clearance of the 
pathogen.  
NK cell secretion of the cytokines TNF-α and IFN-γ is known to play a crucial 
role in granuloma formation following challenge with intracellular bacteria, including 
Mycobacterium avium and Francisella tularensis (74, 75). Granulomas help protect the 
host from bacterial dissemination by isolating infectious foci. 
NK cell activation resulting of infections by intracellular bacteria, such as Listeria 
monocytogenes (76), or protozoa, such as Leishmania (77) or Plasmodium (78), 
involves the production of IL-12 and IL-18 by innate immune cells such as DCs, 
monocyte or macrophages and also the direct interactions between these cells and NK 
cells. Activation receptors on primary NK cells can add to these cells the capacity of 
IFN-γ production and also to the cytotoxic activity (38, 79). Finally, NK cells can 
respond to a variety of chemokines being essential for their recruitment to the site of 
inflammation quickly after infection, as demonstrated in the model of murine 
cytomegalovirus infection in a seminal report from Salazar-Mather and colleagues (80), 
more recently in Toxoplasma gondii infection (81) and reviewed elsewhere (82). 
 
Tuberculosis 
The World Health Organization (WHO) defines Tuberculosis as: 
 “… an infectious bacterial disease caused by Mycobacterium tuberculosis, 
which most commonly affects the lungs. It is transmitted from person to person via 
droplets from the throat and lungs of people with the active respiratory disease. In 
healthy people, infection with Mycobacterium tuberculosis often causes no symptoms, 
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since the person's immune system acts to “wall off” the bacteria. The symptoms of 
active TB of the lung are coughing, sometimes with sputum or blood, chest pains, 
weakness, weight loss, fever and night sweats. Tuberculosis is treatable with a six-
month course of antibiotics.” 
Mycobacterium tuberculosis (Mtb) infection remains a major international health 
problem that is probable to become even more significant in coming years because of 
the high prevalence of human immunodeficiency virus (HIV). Although it is estimated 
that one-third of the world population is currently infected by M. tuberculosis, the 
majority never develop the active disease (83), indicating the ability of human immune 
responses to control the infection. On the other hand, approximately 10% of these 
individuals develop active pulmonary disease. Immune mechanisms involved in this 
differential response by each individual are not clearly explained. Genetic mechanisms 
involved in immune response can also be one of the reasons. 
Mtb is an obligatory aerobic, intracellular pathogen, which preferentially infects 
lung tissue rich in oxygen, but can also spread to other parts of the body.  The tubercle 
bacilli enter the body via the respiratory and are phagocytosed by alveolar 
macrophages as first event in the host-pathogen relationship that decides the outcome 
of infection. Then, an influx of lymphocytes is observed and activated macrophages 
migrate to the site of infection, granuloma is formed. The exponential growth of the 
bacilli is verified and dead macrophages form a caseum containing the bacilli. The 
bacilli can remain forever within the granuloma, get re-activated later or may get 
released into the airways after enormous increase in number, necrosis of bronchi and 
cavitation.  
“Fibrosis represents the last-ditch defence mechanism of the host, where it 
occurs surrounding a central area of necrosis to wall off the infection when all other 
mechanisms failed” (84). 
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 There are some other mechanisms that can be described in immune response 
against TB: the binding of Mtb to monocytes/macrophages by complement, mannose 
and other surface receptors; the fusion of phagolysossome that will allow the Mtb 
degradation; the recruitment of accessory immune cells for the local of inflammatory 
response; the role of reactive oxygen and nitrogen intermediates in the signalling of the 
infection; the IFN-γ and TNF-α mediated anti-mycobacterial effects; the NK cells action 
upon pathogens or infected monocytes; the antigen presentation by APCs to T 
lymphocytes for the development of adaptive response; and finally, the role of B cells 
or antibody in response to Mtb infection (84). 
 
Natural killer cells in Tuberculosis 
 As integrant part of innate immune system, NK cells has been implicated in 
early immune response to a variety of pathogens because they are capable of rapidly 
producing IFN-γ and other immunoregulatory cytokines, as well as lysing specific target 
infected cells always in the absence of prior activation. Some researches have 
demonstrated that NK cells from the peripheral blood contribute for protective immunity 
though IFN-γ of cytotoxic mechanisms, having a huge bactericidal role against Mtb 
(85). 
 The role of NK cell receptors in cytotoxic-mediated killing of mononuclear 
phagocytes infected with an intracellular bacterium has already been reported (85) in 
the same work were they propose that the diminished NK activity during tuberculosis 
infection is probably the 'effect' and not the 'cause' for the disease. Human NK cells are 
known to directly lyse M. tuberculosis-infected monocytes and macrophages in vitro 
(86, 87). In this work, it was found that NKp46 and NKG2D receptors contribute to NK 
cell-mediated lysis of cells infected with Mtb and that reduced functional capacity of NK 
cells is associated with severe manifestations in disease. Denis’ data (88) suggest an 
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important involvement of NK cells in host resistance to TB because of their elevated 
lytic activity against Mtb-infected monocytes. Another study demonstrate the direct 
binding of NKp44 to the mycobacterial surface (89), suggesting that ligands for other 
NK cell receptors may play a role in the specific NK-mediated recognition of Mtb. 
But the NK cells activity in Mtb-infection is not just lyse Mtb-infected cells, these 
cells also actively restrict the infectious agent growth in an apoptosis-dependent but 
Fas/FasL independent manner (90, 91) and this action can be further higher by 
addition of IL-2, IL-12 and glutathione (90). Consistent with the protective role of NK 
cells in tuberculosis (TB), reduced activity of NK cells has been found in active 
pulmonary TB patients (85). Higher levels of pre-NK cells were observed in positive 
tuberculin skin test (TST+) and in TB patients, and in addiction TST+ individuals 
presented levels greatly increased of these cells in comparison to TB (92). Barcelos et 
al. (92) also observed a selective increase in putative activated NK cells of TST+ 
individuals and demonstrated for TST+ and TB patients a distinct correlation profile 
between NK cells and macrophage-like monocytes, suggesting that high levels of 
activated NK cells together with macrophage-like monocytes may be involved in 
protective mechanisms in putative TB-resistant individuals. This finding could be 
important to explain the immunopathogenic context, since these cells contribute for 
protective mechanisms because NK cells have a great ability to proliferate and their 
potential to differentiate into CD3-CD16+CD56+ cells with higher cytotoxic activity. 
Infection with the intracellular pathogen Mtb also results in local lung NK cell 
accumulation and activation, however, their importance in clearing the infection is  not 
clear yet (93, 94). Junqueira-Kipnis et al. (94) explained that NK cells become activated 
during the early response to Mtb infection, but their removal does not substantially 
affect the expression of host resistance. Contrary, Roy et al. (95) identified a potential 
new role for NK cells in maintaining the balance between the regulatory and effector 
arms of the immune response to Mtb infection with the Treg cells lysis. Other findings 
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also suggest NK cells role upon other immune cells in response to Mtb infection, 
promoting expansion of γδ T cells forming immune synapse and by soluble factors 
TNF-α, GM-CSF, and IL-12, but not IFN-γ concluding the NK cells action might be 
beneficial to prevention and control this infection (96). 
 
Aim 
 In the present research on TB patients and healthy contacts it was intended to 
analyze NK cell subsets, surface receptors and intracellular production of cytokines 
(IFN-γ), accounting for the effect in Mycobacterium tuberculosis infection and to the 
progression to pulmonary disease. Establishment of regulatory, cytotoxic and cell-
dependent contact status of NK cells in TB is aimed for an extended characterization of 
NK cells in TB. The main objective is to clarify the role of NK cells in 
immunopathogenesis and hypothetical contribution as targets for therapy interventions. 
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MATERIAL AND METHODS 
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Study population 
The samples used in this study are from two different groups: healthy contacts 
(HC) and pulmonary tuberculosis patients (TB) from Centro de Diagnóstico 
Pneumológico (CDP) de Vila Nova de Gaia. Were studied 38 TB patients 68% male, 
age 45±16 and 15 HC 73% male, age 38±14. Sample number in each experience is 
referred in results (figure or table). Patients with concomitant conditions including 
autoimmune disease, HIV infection, cancer, extrapulmonary TB and other systemic 
disease were excluded from the present analysis. Samples from TB patients were 
collected within the first two weeks of anti-mycobacterial therapy.  
It was obtained informed consent from participants and approval from the Ethics 
Committee of the Faculty of Medicine of the University of Coimbra and of the Faculty of 
Medicine of the University of Porto.  
Blood sampling 
Peripheral blood samples were collected using one K3EDTA tube (3mL), one 
Lithium heparin tube (4mL) and one tube for serum separation (5mL). Serum and 
plasma aliquots were frozen at -80ºC. PBMCs from K3EDTA and samples from Lithium 
heparin tubes were used to flow cytometry and cell culture, respectively. 
 
Complete Blood Cell (CBC) count 
CBC were released in COULTER AC •T diff Analyzer (Beckman Coulter) using 
12µL of whole blood from K3EDTA tube. The Coulter method accurately counts and 
sizes by detecting and measuring changes in electrical resistance when a particle in a 
conductive liquid passes through a small aperture. 
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Enumeration of Lymphocyte subsets 
In order to enumerate lymphocytes and subpopulations, leukocytes from 100µL 
of each peripheral blood sample were labeled with surface monoclonal antibodies 
(mAbs) anti-human: anti-CD4 FITC (clone: OKT4), anti-CD56 PE (clone: HCD56), anti-
CD3 PerCP-Cy5.5 (clone: OKT3), anti-CD8 PE-Cy7 (clone: HIT8a), anti-CD19 APC 
(clone: HIB19), anti-CD16 APC-Cy7 (clone: 3G8) and anti-CD11b Pacific Blue (clone: 
ICRF44). All mAbs were purchased from Biolegend (San José, CA, USA). PBMCs 
were incubated with 30µL of mAbs mix (diluted 1,5:100 in 1x PBS), after red blood cells 
were lysed with 1x RBC lysis buffer (NH4Cl 0.15M,  KHCO3 10mM, EDTA 0.1mM), 
during 30min in the dark at RT. Were added 100µL 4% Formalin and incubated 10min 
at the previous conditions. Cells were washed with cold 1x PBS, for 10min at 300g. 
Supernatant were discarded and cells resuspended in 200µL 1x PBS. Samples were 
analysed in FACSCanto II Flow Cytometer (BD Biosciences, Erembodegem, Belgium). 
 
NK and KIR phenotyping 
To phenotype NK and KIR were used flow cytometry. Whole blood from 
K3EDTA tube were lysed with 1x RBC for 10min at 4ºC and then washed with cold 1x 
PBS. Cells were labeled with extracellular mAbs according to Table 1 scheme during 
30min in the dark at RT. Samples without intracellular labeling were fixed with 100µL 
4% Formalin and incubated 10min at the previous conditions and washed with cold 1x 
PBS for 10min at 300g. Samples with intracellular labeling were fix with 100µL Fix & 
Perm® Medium A (Invitrogen, Carlsbad, CA, USA) for 10min in the dark at RT, washed 
with cold 1x PBS 10min at 300g, were added 100µL Fix & Perm ® Medium B and the 
intracellular mAbs, incubated 30min at RT in the dark and washed for 10min at 300g. 
Supernatant from all samples were discarded and cells resuspended in 200µL 1x PBS. 
Sample data was acquired in FACSCanto II Flow Cytometer. 
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Table 1 – Labeling plan for NK and KIR phenotyping. mAb (clone). 
Fluorochrome FITC PE 
PerCP-
Cy5.5 
PE-Cy7 APC 
APC-
Cy7 
Pacific 
Blue 
m
A
b
s
 a
n
ti
-h
u
m
a
n
 
CD27 
(O323) 
CD57 
(HCD57) 
CD3 
(UCHT1) 
IFN-γ 
(4S.B3) 
CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
1F12 CD158a/h 
(HP-MA4) 
CD3 
(UCHT1) 
- CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
8C11 CD158a/h 
(HP-MA4) 
CD3 
(UCHT1) 
- CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
1F12 CD158b 
(DX27) 
CD3 
(UCHT1) 
- CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
8C11 CD158b 
(DX27) 
CD3 
(UCHT1) 
- CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD27 
(O323) 
CD158a/h 
(HP-MA4) 
CD3 
(UCHT1) 
CD56 
(HCD56) 
CD335 
(9E2) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD27 
(O323) 
CD158e1 
(DX9) 
CD3 
(UCHT1) 
CD56 
(HCD56) 
CD335 
(9E2) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD94 
(DX22) 
CD56 
(HCD56) 
CD3 
(UCHT1) 
IFN-γ 
(4S.B3) 
CD314 
(1D11) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD27 
(O323) 
CD336 
(P44-8) 
CD3 
(UCHT1) 
IFN-γ 
(4S.B3) 
CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD27 
(O323) 
CD337 
(P30-15) 
CD3 
(UCHT1) 
IFN-γ 
(4S.B3) 
CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
CD27 
(O323) 
NKp80 
(5D12) 
CD3 
(UCHT1) 
IFN-γ 
(4S.B3) 
CD56 
(CMSSB) 
CD16 
(3G8) 
CD11b 
(ICRF44) 
Note: intracellular staining referred in bold. 
Flow Cytometry acquired data were analyzed using FlowJo 7.6 software (Tree 
Star Inc, Ashland, USA). 
  
Statistical analysis 
 Statistical tests were performed using GraphPad Prism Version 5.0 software 
(CA, USA). The non-parametric Mann Whitney was used for comparison of TB patients 
and HC. Statistically significant P values are annotated as follows: * p<0.05, ** p<0.01 
and *** p<0.001.  
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RESULTS AND DISCUSSION 
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Complete Blood Cell (CBC) count 
 A CBC is a record of the findings that give the numbers, proportions and 
morphological features of cell components present in peripheral blood. It was 
performed a CBC in TB patients (TB) and in healthy controls (HC) to evaluate the 
possibility of significant changes not only in numbers of lymphocytes, but in all the 
blood components since there are interactions between them that can be important in 
infection and disease. The values of both groups are represented in Table 2. 
Table 2 – Absolute and relative frequencies of white blood cells (WBC) from HC and TB. 
Parameters Units HC TB P 
Leucocytes x10^3/µL 5.88 ±1.03 6.30 ±1.72 0.8106 
Lymphocytes % 31.07 ±5.84 25.40 ±7.73* 0.0423 
Monocytes % 4.95 ±0.83 4.53 ±1.40 0.1735 
Granulocytes % 63.98 ±5.23 69.24 ±8.90 0.0512 
Lymphocytes x10^3/µL 1.82 ±0.43 1.57 ±0.52 0.1845 
Monocytes x10^3/µL 0.28 ±0.06 0.30 ±0.14 0.8178 
Granulocytes x10^3/µL 3.76 ±0.78 4.41 ±1.47 0.2964 
Values represent mean ±SE (HC n=10; TB n=26). *p<0.05 compared to HC (Mann Whitney test). 
 
 All the parameters analysed in the CBC were within the reference values for 
Portuguese populations (97). Comparing the two groups, there is only statistically 
significant difference in the percentage of lymphocytes (p<0,05). This decrease of 
lymphocytes is supported by several studies (98-100), other study found this decrease 
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in 46% of the untreated TB patients but a lymphocytosis in 6% of TB patients (101) and 
two other reports, relate the lymphopenia with the severity of the disease (102, 103).  
 
Enumeration of lymphocyte subsets 
 Lymphocyte subsets reference values are used to monitor infectious diseases 
including tuberculosis. Using Flow Cytometry, these subsets were evaluated by the 
differential surface expression of some markers: CD3+ (T cells); CD3+CD4+ (helper T 
cells); CD3+CD8+ (cytotoxic T cells); CD3-CD19+ (B cells) and CD3-CD56+ (NK cells). 
With Flow Cytometry data (percentage of cells) and the absolute values for 
lymphocytes of the CBC it was possible to calculate the absolute numbers of each 
lymphocyte subset. 
Figure 4 – A, B – Representative dot plots of lymphocyte sub-populations in TB and HC, respectively. C – 
Lymphocyte sub-populations percentage in TB (gray; n=11) and HC (white; n=9). D – Absolute number of 
lymphocyte sub-populations in TB and HC. *p<0.05 compared to HC (Mann Whitney test). 
 
 In terms of percentages of cells there are no statistically significant differences 
and the distribution is similar between both groups. When the comparison is made in 
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number of cells there are important changes to report. All the lymphocytes subsets are 
decreased in TB group, particularly cytotoxic T cells (p=0.0184), except B cells subset. 
Since the number of lymphocytes was lower in TB, as was observed in CBC, was 
expected that the same happen in its subsets. In the literature, the results for this type 
of lymphocyte counts are not consensual. Wu et al. (104) observed a decrease in CD3+ 
and CD3+CD4+, an increase in B cells and CD3+CD8+ and a similar numbers in NK 
cells between TB and controls. Ainslie et al. (105) also found decrease in CD3+CD4+ 
and an increase in CD3+CD8+. Rodrigues et al. (106) and Beck et al. (107) describe a 
decrease in both CD3+CD4+ and CD3+CD8+. Uppal et al. (108) observed a decrease in 
CD3+CD4+ but similar levels for CD3+CD8+, Hernandez et al. (109) found significant 
lower values for B cells and similar for CD3+. These contrasting results may be 
explained by the possibility that the modifications of PBMCs change over time since 
immunological factors seem to change in concentrations over the time. 
 
Total NK cells 
 NK cells are lymphocytes phenotypically characterized as CD3-CD56+. Once 
the work focused the NK cells, it was performed another evaluation of this cells in TB 
and HC using labelling with mAbs in other fluorochromes.  
Figure 5 - A, B – Representative dot plots of total NK cells (CD3 vs. CD56) in TB and HC, respectively. 
C – Analysis of total NK cells (CD3
-
CD56
+
) in peripheral blood of TB (gray, n=27) and HC (white, n=9). 
D – Mean fluorescence intensity of CD56 and CD3 in NK cells of TB and HC. Gated lymphocytes were 
used in analysis. Not significant results. (Mann Whitney test). 
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Once again the results only present a trend to a decrease of NK cells in TB 
comparatively to HC. As was referred above, other studies also didn’t find significant 
differences between these two groups. It is important to report that the mAbs used in 
this labelling seems to be unstable since the population CD3+CD56+ is not according to 
what was expected. The mean of fluorescence intensity for CD3 and CD56 in CD3-
CD56+ population in both groups was analysed and CD56 was no significantly increase 
in HC population. These increase that mean a higher expression of this molecule can 
be due to the instability of the fluorochrome so, in the future, different fluorochromes 
should be tested.  
 For CD3-CD56+ populations in both TB and HC were evaluated theirs 
expression of CD16 as well as their distribution in terms of CD27/CD11b. The results 
are represented in Table 3. 
Table 3 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD3
-
CD56
+
 in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 62.83 ±20.70 57.21 ±17.45 0.5837 
MFI CD16 1336.33 ±381.58 1077.04 ±684.55 0.0860 
CD11b
-
 CD27
+
 
% 1.25 ±1.23 1.17 ±1.23 0.9272 
MFI CD27 2177.75 ±1450.53 1240.08 ±997.29* 0.0140 
MFI CD11b 261.25 ±54.00 243.95 ±73.40 0.7453 
CD11b
+
 CD27
+
 
% 1.92 ±1.40 7.69 ±11.54* 0.0235 
MFI CD27 1163.33 ±289.48 841.96 ±337.14* 0.0137 
MFI CD11b 1822.22 ±479.18 1739.70 ±800.74 0.4650 
CD11b
+
 CD27
-
 
% 64.94 ±20.51 65.59 ±15.28 0.8982 
MFI CD27 13.52 ±28.14 65.33 ±84.43 0.0531 
MFI CD11b 2228.78 ±503.08 2144.59 ±807.88 0.6348 
CD11b
-
 CD27
-
 
% 31.89 ±20.63 25.57 ±14.33 0.4216 
MFI CD27 37.77 ±30.89 49.09 ±37.20 0.5211 
MFI CD11b 135.29 ±53.40 122.73 ±51.06 0.6090 
Values represent mean ±SE (HC n=27; TB n=9). *p<0.05 compared to HC. (Mann Whitney test) 
 
 The distribution of these surface makers will be explained in more detail below, 
where it is only important to refer that the CD16 expression tends to decrease and it is 
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observed a higher percentage in CD11b+CD27+ subset in TB patients, probably due to 
a decrease in NK cell maturation. The partial decrease in CD16 expression does not 
corroborate a previous study that reports a great increase of CD16 expression in TB 
patients (110). 
 
Proposal of NKp46 for NK cell definition 
 NKp46, a natural cytotoxicity receptor, is expressed almost exclusively in NK 
cells. Recently this molecule is being referred as a better markers for NK cells than 
CD56, so it as analysed its expression of CD3- subset of lymphocytes (111).  
 
 It was observed a higher percentage of CD3- cells expressing NKp46 in TB 
relatively to HC, but with a decrease level of expression of this receptor. The role of 
NKp46 in lysis of infected monocytes with Mtb is already defined. One study correlates 
this capacity of lyse with increased expression of mRNA of NKp46 receptor and also 
refers that this expression in reduced in TB patients (86). Results presented here are 
concordant because despite of the higher percentage of NKp46+ cells present in TB, its 
expression tends to decrease. 
 When the expression of CD16 and subset distribution of CD27/CD11b was 
evaluated (Table 4), once again it was observed an increase in CD11b+CD27+ (not 
Figure 6 – A, B – Representative dot plots of NK cells (CD3
 
vs. NKp46) in TB and HC, respectively. C – 
Analysis of NK cells (CD3
-
NKp46
+
) in peripheral blood of TB (gray, n=27) and HC (white, n=9). D – Mean 
fluorescence intensity of NKp46 and CD3 in NK cells of TB and HC. Gated lymphocytes were used in 
analysis. (Mann Whitney test). 
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statistically significant) in TB patients, with a slight decreased expression of CD27 in 
this subset. This result points towards a more immature form of cells in TB patients. 
Table 4 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD3
-
NKp46
+
 in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 84.51 ±6.09 80.84 ±13.35 0.7285 
MFI CD16 1478.56 ±453.33 1174.26 ±717.53 0.0734 
CD11b
-
 CD27
+
 
% 0.26 ±0.38 0.43 ±0.86 0.7549 
MFI CD27 892.75 ±764.06 622.40 ±224.02 0.5249 
MFI CD11b 127.71 ±79.46 232.96 ±93.04* 0.0102 
CD11b
+
 CD27
+
 
% 5.29 ±3.71 11.45 ±15.41 0.4762 
MFI CD27 685.25 ±107.39 524.15 ±139.35** 0.0045 
MFI CD11b 2095.00 ±218.10 1752.31 ±611.03* 0.0403 
CD11b
+
 CD27
-
 
% 91.32 ±3.89 85.03 ±15.04 0.4321 
MFI CD27 17.07 ±38.57 44.83 ±58.09 0.1001 
MFI CD11b 2476.22 ±513.43 2351.07 ±829.02 0.4876 
CD11b
-
 CD27
-
 
% 3.12 ±3.07 3.10 ±3.10 0.9418 
MFI CD27 16.75 ±22.38 61.53 ±62.26 0.0929 
MFI CD11b 113.43 ±31.22 177.76 ±89.13* 0.0258 
Values represent mean ±SE (HC n=27; TB n=9). *p<0.05 **p<0.01 compared to HC (Mann Whitney test). 
 
 When the values of CD3-CD56+ were compared to CD3-NKp46+, the first 
observation was that CD3-NKp46+ population is smaller, meaning that if only CD3-
NKp46+ was considering as NK cells, probably would be lost a lot of information. So, 
CD3-CD56+ still remain as the better characterization for NK cells. 
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Figure 7– CD56 vs. NKp46 as NK cell-speciifc phenotype markers: correlation of CD3-CD56+ and CD3-
NKp46+ cells in peripheral blood of pulmonary tuberculosis (TB) patients and healthy contacts (HC). Gated 
lymphocytes were used for comparisons. No correlations were found in TB (r
2
=0.0595) and HC (r
2
=0.144). 
  
Then CD3-CD56+NKp46+ population was studied and the results are 
represented in Figure 8 and Table 5. 
 
Figure 8 – A, B – Representative dot plots of CD3
-
 using CD56 and NKp46 as surface markers to 
distinguish different subsets in TB and HC, respectively. C – Analysis of NK cells (CD56
+
NKp46
+
) in 
peripheral blood of TB (gray, n=27) and HC (white, n=9). D – Mean fluorescence intensity of NKp46 and 
CD56 in NK cells of TB and HC. Gated lymphocytes were used in analysis. *p<0.05 compared to HC. 
(Mann Whitney test). 
  
Percentage of cell CD3-CD56+NKp46+ doesn’t have significant variation 
between two groups. Looking to mean of fluorescence intensity, there is a significant 
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higher expression of CD56 in HC group. CD16 percentage of cells and expression are 
similar in both groups. CD27/CD11b subsets are concordant with previous results here 
presented: increase of CD11b+CD27+ in TB patients. In the literature are not studies of 
these characterizations in CD3-CD56+NKp46+. 
 
Table 5 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD3
-
CD56
+
NKp46
+
 in TB and 
HC. Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 81.97 ±9.00 78.22 ±13.85 0.5588 
MFI CD16 1372.78 ±411.39 1126.74 ±685.40 0.1002 
CD11b
-
 CD27
+
 
% 0.14 ±0.19 0.43 ±1.03 0.8810 
MFI CD27 925.71 ±1169.03 618.88 ±229.07 0.3326 
MFI CD11b 104.50 ±68.72 207.88 ±80.04** 0.0083 
CD11b
+
 CD27
+
 
% 5.68 ±3.98 11.33 ±16.18 0.7701 
MFI CD27 723.00 ±114.56 527.69 ±147.48** 0.0028 
MFI CD11b 2089.75 ±353.92 1692.81 ±685.73 0.1180 
CD11b
+
 CD27
-
 
% 91.33 ±4.51 85.09 ±15.74 0.5226 
MFI CD27 12.39 ±26.55 44.47 ±57.55 0.1048 
MFI CD11b 2392.56 ±497.24 2257.30 ±806.19 0.5346 
CD11b
-
 CD27
-
 
% 2.85 ±3.40 3.15 ±3.63 1.0000 
MFI CD27 4.23 ±6.98 48.48 ±51.14* 0.0130 
MFI CD11b 107.13 ±55.34 168.31 ±71.41* 0.0194 
Values represent mean ±SE (HC n=27; TB n=9). *p<0.05 **p<0.01 compared to HC (Mann Whitney test). 
 
  
Total NK cell – Classic subsets (CD56/CD16) 
 Classically, NK cells are characterized by CD3- and by the intensity of CD56 
(dim or bright). Approximately 90% of peripheral NK cells present low density for CD56 
and high levels of CD16. The remaining 10% express high levels of CD56 and are 
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negative for CD16 (112). This last subset is more immature, it is thought that during 
their development and cytotoxicity acquisition NK cells pass through three stages: 
CD56dimCD16- (immature), CD56brightCD16- (“regulatory”) and CD56dimCD16+ 
(cytotoxic). In this study was considered another stage: CD56brightCD16+ as a “pro-
inflammatory” stage. 
 
Figure 9 – A, B – Representative dot plots of NK cell subsets according to CD56 and CD16 surface 
expression in TB and HC, respectively. C – Analysis of NK cell sub-sets in peripheral blood of TB (gray, 
n=29) and HC (white, n=10). D – Mean fluorescence intensity of CD56 and CD16 in NK cell subsets of TB 
and HC. Gated lymphocytes were used in analysis. *p<0.05 **<0.01 compared to HC. (Mann Whitney test) 
 
 Data represent NK cells normalized for a total of 100%. As can be observed in 
first graph (C) there are no statistically significant changes in both of groups for NK cell 
subsets, but the values for more mature subsets in TB patients tend to be increased. 
The mean of fluorescence intensity has some variations in CD16 expression with a 
significant decrease in TB patients. This means that although TB patients present 
these increased values in more mature subsets, NK cells have less cytotoxic capacity 
in comparison with HC. 
 Previous data supports these results referring a decrease in CD3-CD16-
/+CD56dim and an increase in CD3-CD16-/+CD56bright in TST+ controls (92). However, 
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Bozzano et al. (113) found decreased proportions of CD16+/-CD56bright and increased 
values of CD16+CD56dull subsets in TB. 
 CD27/CD11b expression was evaluated for each subset. Only CD56brightCD16- 
subset presented differences in these markers as well as in mean of fluorescence 
intensity (Table 6). 
 
Table 6 – Percentage of cells in each CD27/CD11b subset for CD3
-
CD56
bright
CD16
-
 in TB and HC. Means 
of fluorescence intensity for CD27 and CD11b. 
  HC TB P 
CD11b
-
 CD27
+
 
% 0.46 ±0.93 2.98 ±3.46* 0.0355 
MFI CD27 2365.00 ±481.09 1757.06 ±735.53 0.2040 
MFI CD11b 346.33 ±66.51 208.84 ±72.65* 0.0300 
CD11b
+
 CD27
+
 
% 23.17 ±14.43 18.85 ±13.72 0.4556 
MFI CD27 1242.75 ±171.97 1193.86 ±250.42 0.7144 
MFI CD11b 2163.25 ±570.82 1485.43 ±465.76** 0.0068 
CD11b
+
 CD27
-
 
% 74.31 ±15.84 71.42 ±16.45 0.5516 
MFI CD27 121.09 ±52.79 80.22 ±55.90 0.0592 
MFI CD11b 2396.90 ±416.10 1785.07 ±609.98** 0.0033 
CD11b
-
 CD27
-
 
% 2.07 ±2.38 6.75 ±6.84* 0.0295 
MFI CD27 137.97 ±84.49 120.73 ±92.21 0.6321 
MFI CD11b 261.86 ±81.04 304.56 ±76.96 0.2740 
Values represent mean ±SE (HC n=29; TB n=10). *p<0.05 **p<0.01 compared to HC (Mann Whitney test). 
 
 Significant changes were found in CD11b- subsets, with an increased 
expression in TB patients. This alteration is also observed in CD11b+ subsets with a 
sharp significantly lower mean of fluorescence intensity. CD11b expression is related 
with gain of maturity, as will be explained next. The subset of these findings in the 
second more immature of the NK cells, and this lack of CD16 expression gives an even 
more immaturity phenotype to TB patients cells in CD3-CD56brightCD16- subset. 
39 
 
CD27/CD11b 
 Recently, Fu et al. (34), made some progress in NK cell phenotyping relatively 
to CD27/CD11b expression and defined four stages that describe NK cell development: 
CD11b-CD27-, CD11b-CD27+, CD11b+CD27+ and CD11b+CD27-. So, during their 
maturation cells acquire and lose CD27 and acquire CD11b. In peripheral blood NK 
cells have their more mature stage: CD11b+CD27-. 
 Data of this kind of analysis is represented in Figure 10. There are no 
differences in subset distribution of NK cells in TB and HC. In other words, according to 
this characterization NK cells in terms of CD27/CD11b, TB and HC have the same 
level of development. 
 
Figure 10 – A, B – Representative dot plots of NK cells and NK cell subsets according to CD27 and 
CD11b surface expression in TB and HC, respectively. C – Analysis of NK cell subsets in peripheral blood 
of TB (gray, n=29) and HC (white, n=11). D – Mean fluorescence intensity for CD27 and CD11b in NK cell 
subsets of TB and HC. Gated lymphocytes were used in analysis. *p<0.05 compared to HC (Mann 
Whitney test). 
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IFNγ production by NK cells 
 The IFNγ is the key cytokine for a protective immune response against Mtb 
(114). This cytokine is produced mainly by CD4+, CD8+ T cells and NK cells (114). Here 
it was evaluated the intracellular IFNγ production by NK cells. As observed in  
Figure 11, TB patients present a significantly higher percentage of IFNγ+ NK cells 
comparatively to HC. This can be explained because in TB patients, NK cells are 
producing great levels of this cytokine to recruit macrophages to kill intracellular Mtb.  
 
Figure 11 – A – Representative histogram of IFNγ intracellular expression in NK cell (CD3
-
CD56
+
) of TB 
(red) and HC (blue). B – Analysis of IFNγ intracellular expression in NK cell in peripheral blood of TB (gray, 
n=23) and HC (white, n=10). C – Mean fluorescence intensity of IFNγ in NK cells of TB and HC. Gated 
lymphocytes were used in analysis. **p<0.01 compared to HC (Mann Whitney test). 
 
Bozzano F et al. (113) made some observations in NK cell phenotype as well as 
IFNγ production related with the course of treatment. They report that before treatment 
cells were producing less IFNγ than controls, but after treatment these levels of 
production were equivalent. What was observed here was a massive production of 
IFNγ in TB comparatively with HC, that can be due to treatment. 
 
CD57 as a marker for NK cell terminal differentiation 
 Lopez-Verges et al. (35) suggested recently that NK cells expressing CD57 
represent a subset of mature and terminally differentiated cells. Data presented here 
demonstrate a significantly increase (p<0.001) of CD57 expressing cells in TB patients 
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with a partial increase in intracellular IFNγ in these cells represented in Figure 12. In 
terms of CD27/CD11b distribution, results for CD57+ subset are concordant with what 
was expected: almost of cells are CD11b+CD27-, confirming their high degree of 
maturation (Table 7). CD16 expression is not according with this state of differentiation; 
it was expected higher percentage of cells expressing this marker. This may be due to 
instability of marker once cells were first extracellular labelled and than permeabilized, 
so there may be some interference with extracellular labelling of this marker. 
 
Figure 12 – A - Representative histogram of CD57 surface expression in NK cell (CD3
-
CD56
+
) of TB (red) 
and HC (blue). B – Analysis of CD57 expression on NK cell in peripheral blood of TB (gray, n=20) and HC 
(white, n=11). C – Mean fluorescence intensity of CD57 in NK cells of TB and HC. D – Representative 
histogram of IFNγ intracellular expression on NK cell CD57
+
 for TB (red) and HC (blue). E – Anaysis of 
IFNγ intracellular expression on NK cells CD57
+
. F – Mean fluorescence intensity of IFNγ in NK cells 
CD57
+
 in TB and HC. Gated lymphocytes were used in analysis. ***p<0.001 compared to HC (Mann 
Whitney test). 
 
 The meaning of these results can be explained by the NK response to infection, 
once Lopez-Verges (35) explained that CD57+ cells have more lytic activity and higher 
sensibility to stimulation. According to the same author, these cells also express higher 
levels of NCRs being well prepared to oppose infected cells with Mtb. 
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Table 7 – Percentage of cells expressing CD16 and in each CD27/CD11b subset for CD3
-
CD56
+
CD57
+
 in 
TB and HC. Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 16.92 ±25.48 15.38 ±18.25 0.8688 
MFI CD16 600.27 ±512.45 560.05 ±454.17 0.5494 
CD11b
-
 CD27
+
 
% 0.01 ±0.03 0.00 ±0.00 - 
MFI CD27 - - - 
MFI CD11b - - - 
CD11b
+
 CD27
+
 
% 1.54 ±1.00 1.52 ±1.50 0.5222 
MFI CD27 605.50 ±90.39 797.75 ±331.35 0.2020 
MFI CD11b 1904.90 ±1227.87 2302.60 ±1422.69 0.3442 
CD11b
+
 CD27
-
 
% 89.92 ±7.75 90.27 ±11.35 0.5084 
MFI CD27 245.91 ±46.15 332.70 ±130.77* 0.0475 
MFI CD11b 1706.91 ±1583.26 1823.65 ±1022.66 0.3529 
CD11b
-
 CD27
-
 
% 8.53 ±7.61 8.22 ±11.12 0.3957 
MFI CD27 122.97 ±49.24 127.71 ±27.72 0.2734 
MFI CD11b 315.00 ±183.85 273.43 ±46.70 0.3664 
Values represent mean ±SE (HC n=20; TB n=11). *p<0.05 compared to HC (Mann Whitney test). 
 
Surface expression of CD94 and NKG2D 
 CD94 is a Killer cell lectin-like receptor belonging to subfamily D, number 1 
(also known as KLRD1). This receptor appears usually as heterodimers with elements 
of NKG2 family. NKG2D, a member of NKG2 family, is an activating receptor. CD94 
can also appears linked with NKG2A (inhibitory receptor) and NKG2C (activatory 
receptor) as well as in form of oligodimer. Here as observed the co-expression of CD94 
and NKG2D in TB and HC. 
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Figure 13 – A, B – Representative dot plots of NK cells and NK cell subsets according to CD94 and 
NKG2D surface expression in TB and HC, respectively. C – Analysis of NK cell subsets in peripheral blood 
of TB (gray, n=10) and HC (white, n=9). D – Mean fluorescence intensity for CD94 and NKG2D in NK cell 
subsets of TB and HC. Gated lymphocytes were used in analysis. *p<0.05, **p<0.01 compared to HC 
(Mann Whitney test). 
 
Data presented in Figure 13 represents CD94/NKG2D populations in TB and 
HC. It can be observed a significant increase in double positive subset in TB patients 
as well as higher levels of CD94 expression in all subsets relatively to HC. NKG2D 
expression tends to increase in all subsets of TB patients. 
Table 8 shows CD16 and intracellular IFNγ in each CD94/NKG2D subset. The 
significance of those NK cell subsets remains unclear. Further analysis dissecting 
NKG2A and NKG2C in those cells in needed. 
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Table 8 – Percentage of cells expressing CD16 and intracellular IFNγ in each CD94/NKG2D subset in TB 
and HC. Means of fluorescence intensity for CD16 and IFNγ. 
  HC TB P 
CD94
-
 NKG2D
+
 
% CD16 32.91 ±33.56 50.89 ±31.31 0.3154 
MFI CD16 436.89 ±591.87 576.80 ±663.35 0.1207 
% IFNγ 33.21 ±15.13 44.42 ±14.49 0.1912 
MFI IFNγ 303.22 ±72.57 281.40 ±81.58 0.4470 
CD94
+
 NKG2D
+
 
% CD16 39.77 ±24.19 58.86 ±20.66 0.0653 
MFI CD16 306.22 ±325.78 423.40 ±440.73 0.0535 
% IFNγ 39.48 ±3.75 44.29 ±6.99 0.2528 
MFI IFNγ 271.78 ±44.67 277.00 ±57.82 0.8702 
CD94
+
 NKG2D
-
 
% CD16 54.17 ±10.25 53.15 ±22.65 0.8421 
MFI CD16 288.67 ±89.70 325.00 ±141.82 0.7197 
% IFNγ 40.08 ±10.02 40.71 ±9.40 0.7802 
MFI IFNγ 286.78 ±56.80 280.10 ±57.68 0.7802 
CD94
-
 NKG2D
-
 
% CD16 40.66 ±13.39 45.50 ±35.23 0.8380 
MFI CD16 345.78 ±106.31 225.88 ±93.59* 0.0384 
% IFNγ 37.74 ±15.15 32.78 ±29.21 0.4132 
MFI IFNγ 301.89 ±87.13 264.71 ±48.07 0.4698 
Values represent mean ±SE (HC n=10; TB n=9). *p<0.05 compared to HC (Mann Whitney test). 
 
Other Natural Cytotoxicity Receptors (NCRs) 
 Natural cytotoxicity receptors (NCRs) play a major role in NK cell cytotoxicity 
against transformed cells (47). NKp46, NKG2D and CD94 NCRs have already been 
discussed in the results. It was also analysed NKp44, NKp30 and NKp80 positive cells, 
expression, intracellular IFNγ, CD16 and CD27/CD11b positive cells and expression on 
TB and HC. In data it can be observed increased levels of positive cells for all of these 
NCRs as well as higher levels of intracellular IFNγ in TB patients (Figure 14). The most 
significant increase in NCRs was observed for NKp80 and this receptor is also the 
most expressed in NK cells in both groups. NKp30 is not only the least represented in 
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NK cells from two groups, but also the receptor that presented the least increase in TB 
patients. Although in terms of expression NKp30 was significantly increased in TB 
patients. NKp44 is present in a vast majority of NK cells in both groups however is 
increased in TB patients. 
 Intracellular IFNγ positive cells were significantly elevated in all NCRs positive 
cells and its expression tends to be elevated in TB patients.  
NKp44+CD16+ cells decreased in both groups regarding to expected for cells in 
high degree of maturation (Table 9).  
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Figure 14 – 1 – Results for NKp44+ NK cells (TB n=23, HC n=10). 2 – Results for NKp30+ NK cells (TB 
n=19, HC n=9). 3 – Results for NKp80+ NK cells (TB n=16, HC n=10). A – Representative histogram of 
each NCR surface expression in NK cell (CD3
-
CD56
+
) of TB (red) and HC (blue). B – Analysis of each 
NCR expression on NK cell in peripheral blood of TB (gray) and HC (white). C – Mean fluorescence 
intensity of each NCR in NK cells of TB and HC. D – Representative histogram of IFNγ intracellular 
expression on NK cell positive for each NCR in TB (red) and HC (blue). E – Analysis of IFNγ intracellular 
expression on NK cells positive for each NCR. F – Mean fluorescence intensity of IFNγ in NK cells positive 
for each NCR in TB and HC. Gated lymphocytes were used in analysis. *p<0.05, **p<0.01 compared to 
HC (Mann Whitney test). 
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 CD27/CD11b subsets of NCRs positive populations had no significant 
differences except for NKp80 in CD11b+CD27- subset were can be observed an 
increase in TB patients (Table 11). But in general, almost all cells express CD11b and 
are negative for CD27 in both groups. 
 
Table 9 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD3
-
CD56
+
NKp44
+
 in TB and 
HC. Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 43.00 ±26.69 43.79 ±24.50 1.0000 
MFI CD16 313.80 ±280.27 409.26 ±573.55 0.6665 
CD11b
-
 CD27
+
 
% 0.00 ±0.01 0.00 ±0.01 0.1951 
MFI CD27 - - - 
MFI CD11b - - - 
CD11b
+
 CD27
+
 
% 0.94 ±0.66 0.78 ±1.37 0.0575 
MFI CD27 716.80 ±107.19 908.78 ±302.37 0.1040 
MFI CD11b 2101.60 ±1067.03 2358.00 ±984.53 0.2992 
CD11b
+
 CD27
-
 
% 88.46 ±12.74 92.40 ±8.37 0.3177 
MFI CD27 285.60 ±32.81 368.65 ±110.48* 0.0243 
MFI CD11b 1936.60 ±1704.04 2435.91 ±2366.98 0.4220 
CD11b
-
 CD27
-
 
% 10.60 ±12.88 6.82 ±8.43 0.5054 
MFI CD27 132.58 ±41.36 209.36 ±101.21** 0.0090 
MFI CD11b 320.44 ±52.50 485.45 ±192.35** 0.0023 
Values represent mean ±SE (HC n=23; TB n=10). *p<0.05 and **p<0.01 compared to HC (Mann Whitney 
test). 
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Table 10 – Percentage of cells each CD27/CD11b subset for CD3
-
CD56
+
NKp30
+
 in TB and HC. Means of 
fluorescence intensity for CD27 and CD11b. 
  HC TB P 
CD11b
-
 CD27
+
 
% 0.00 ±0.00 0.00 ±0.00 - 
MFI CD27 - - - 
MFI CD11b - - - 
CD11b
+
 CD27
+
 
% 0.58 ±0.88 0.63 ±0.61 0.2476 
MFI CD27 786.50 ±106.59 862.58 ±257.60 0.7702 
MFI CD11b 2176.63 ±914.82 2548.58 ±2100.65 0.6517 
CD11b
+
 CD27
-
 
% 89.27 ±10.31 92.00 ±7.24 0.5063 
MFI CD27 280.22 ±47.76 355.42 ±95.16* 0.0237 
MFI CD11b 1861.56 ±1402.46 2315.89 ±2562.20 0.3252 
CD11b
-
 CD27
-
 
% 10.16 ±10.63 7.36 ±7.00 0.5882 
MFI CD27 143.00 ±67.12 182.00 ±74.96* 0.0270 
MFI CD11b 346.56 ±107.89 399.61 ±124.67 0.2688 
Values represent mean ±SE (HC n=19; TB n=9). *p<0.05 compared to HC (Mann Whitney test). 
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Table 11 – Percentage of cells each CD27/CD11b subset for CD3
-
CD56
+
NKp80
+
 in TB and HC. Means of 
fluorescence intensity for CD27 and CD11b. 
  HC TB P 
CD11b
-
 CD27
+
 
% 0.00 ±0.01 0.00 ±0.01 - 
MFI CD27 - - - 
MFI CD11b - - - 
CD11b
+
 CD27
+
 
% 0.45 ±0.88 0.41 ±0.54 0.3292 
MFI CD27 825.89 ±59.10 969.36 ±263.91 0.2703 
MFI CD11b 1997.00 ±989.74 2929.00 ±1397.04 0.0832 
CD11b
+
 CD27
-
 
% 89.13 ±8.38 94.81 ±6.25* 0.0287 
MFI CD27 277.10 ±46.22 397.88 ±108.91** 0.0013 
MFI CD11b 1715.70 ±1331.58 2679.25 ±2184.25 0.0775 
CD11b
-
 CD27
-
 
% 10.42 ±8.72 4.77 ±6.15 0.0775 
MFI CD27 127.86 ±61.08 241.50 ±114.56** 0.0017 
MFI CD11b 361.50±136.09 574.81 ±214.75** 0.0044 
Values represent mean ±SE (HC n=16; TB n=10). *p<0.05 and **p<0.01 compared to HC (Mann Whitney 
test). 
 
Inhibitory KIR: KIR2DL1, KIR2DL2 and KIR3DL1 
 Killer cell immunoglobulin-like receptors (KIRs) belong to a highly polymorphic 
family of receptors that recognise MHC-class I molecules. KIR acquisition is a late 
event during NK cell maturation. These receptors are mostly inhibitors but they may 
also have activating functions depending on the length of their cytoplasmic tail. 
Inhibitory KIRs recognise MHC-class I molecules and suppress the cytotoxic activity of 
NK cells. 
 Based on David G et al. (115) work descriptions, KIR2DL2 and KIR2DL1 
phenotypes were analysed in TB patients and HC using a combination of mAbs (Figure 
15 – 1, 2). Also KIR2DL2/DL3 and KIR3DL1 NK positive cells were analysed through 
the use of specific mAbs (CD158b and CD158e, respectively). 
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 The percentage of KIR2DL2, KIR2DL1 and KIR3DL1 positive cells tends to 
decrease in TB patients and also their expression tends to be decreased. KIR3DL1 is 
significantly decreased in its expression in TB patients (Figure 15 – 1, 2 and 4). 
 
Figure 15 – 1-2 A-B – Representative dot plots of NK cells expressing KIR2DL2 (1) and KIR2DL1 (2) in 
TB and HC, respectively.1-2 C – Analysis of NK cell KIR2DSL2
+
 (1) (TB n=28; HC=11) and KIR2DL1
+
 (2) 
(TB n=29; HC n=11) in peripheral blood of TB and HC. 1-2 D – Mean fluorescence intensity for CD158b 
and 1F12 in NK cell KIR2DL2
+
 (1) and for CD158b and 8C12 in NK cell KIR2DL1
+ 
(2) of TB and HC. 3-4 A 
– Representative histogram of CD158b (3) and CD158e (4) expression in NK cells from TB (red) and HC 
(blue). 3-4 B – Analysis of CD158b (3) (TB n=28; HC n=11) and CD158e (4) (TB n=25; HC n=9) 
expression on NK cell in peripheral blood of TB and HC. 3-4 C – Mean fluorescence intensity of CD158a/h 
(3) and CD158e (4) in NK cells of TB and HC. Gated lymphocytes were used in analysis. *p<0.05 
***p<0.001 compared to HC (Mann Whitney test). 
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Table 12 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for KIR2DL2
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 87.55 ±14.83 82.44 ±19.73 0.4261 
MFI CD16 1604.00 ±836.03 1337.32 ±810.45 0.2816 
CD11b
-
 CD27
+
 
% 0.00 ±0.01 0.10 ±0.20 0.2239 
MFI CD27 537.00 ±0.00 2665.14 ±2036.33 - 
MFI CD11b 66.10 ±0.00 218.50 ±132.18 - 
CD11b
+
 CD27
+
 
% 0.77 ±0.93 1.15 ±1.26 0.5368 
MFI CD27 2851.25 ±1845.23 2990.47 ±1275.83 0.7300 
MFI CD11b 1760.13 ±513.90 1775.89 ±639.24 0.9365 
CD11b
+
 CD27
-
 
% 95.92 ±4.09 95.99 ±3.49 0.7667 
MFI CD27 39.86 ±13.29 41.68 ±21.01 0.7431 
MFI CD11b 2618.18 ±1056.50 2414.29 ±1056.85 0.4729 
CD11b
-
 CD27
-
 
% 3.32 ±4.09 2.76 ±3.20 0.8508 
MFI CD27 41.71 ±30.21 84.98 ±145.84 0.5259 
MFI CD11b 256.36 ±74.37 287.83 ±62.65 0.5879 
Values represent mean ±SE (HC n=28; TB n=11). Not significant data (Mann Whitney test). 
 
 Tables 12, 13, 14 and 15 show the results for CD16 and CD27/CD11b 
expression in NK cells expressing referred inhibitory KIRs. All cells present similar 
levels of differentiation as it can be observed by the surface expression of those 
markers.  
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Table 13 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for KIR2DL1
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 71.89 ±19.43 75.28 ±17.35 0.5547 
MFI CD16 1379.82 ±670.05 1027.66 ±467.92 0.1299 
CD11b
-
 CD27
+
 
% 0.16 ±0.35 0.46 ±1.26 0.9271 
MFI CD27 2280.50 ±593.50 1117.60 ±591.01 0.3810 
MFI CD11b 412.00 ±39.00 278.80 ±26.81 0.0952 
CD11b
+
 CD27
+
 
% 10.36 ±9.59 9.08 ±10.55 0.6135 
MFI CD27 2140.63 ±539.81 1925.62 ±1360.13 0.3414 
MFI CD11b 2882.50 ±670.32 2893.71 ±1440.10 0.6783 
CD11b
+
 CD27
-
 
% 83.44 ±10.55 85.67 ±12.42 0.5148 
MFI CD27 58.61 ±31.44 85.44 ±56.64 0.2256 
MFI CD11b 2539.36 ±1347.64 2333.41 ±806.90 0.9156 
CD11b
-
 CD27
-
 
% 6.04 ±8.96 4.79 ±6.40 0.6266 
MFI CD27 95.50 ±80.20 80.08 ±106.94 0.3511 
MFI CD11b 276.11 ±76.15 292.16 ±118.10 0.3787 
Values represent mean ±SE (HC n=29; TB n=11). Not significant data (Mann Whitney test). 
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Table 14 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD158b
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 92.02 ±12.54 89.62 ±11.54 0.4260 
MFI CD16 1545.82 ±794.65 1291.04 ±888.48 0.2886 
CD11b
-
 CD27
+
 
% 0.03 ±0.10 0.07 ±0.16 0.1404 
MFI CD27 4069.00 ±0.00 3660.80 ±3595.56 - 
MFI CD11b 127.00 ±0.00 154.31 ±57.28 - 
CD11b
+
 CD27
+
 
% 1.10 ±1.03 1.15 ±1.15 0.9251 
MFI CD27 3432.13 ±1129.40 2429.39 ±936.38 0.0610 
MFI CD11b 1962.38 ±474.60 2280.78 ±1471.33 0.8390 
CD11b
+
 CD27
-
 
% 95.89 ±4.98 97.50 ±2.56 0.3652 
MFI CD27 49.33 ±19.11 52.07 ±22.40 0.6209 
MFI CD11b 2410.27 ±899.16 2380.04 ±931.22 0.8883 
CD11b
-
 CD27
-
 
% 2.97 ±5.13 1.29 ±1.83 0.1381 
MFI CD27 78.37 ±55.76 62.53 ±56.44 0.8367 
MFI CD11b 161.82 ±31.10 182.28 ±32.89 0.0714 
Values represent mean ±SE (HC n=28; TB n=11). Not significant data (Mann Whitney test). 
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Table 15 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD158e
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 95.29 ±3.53 80.49 ±28.29 0.3564 
MFI CD16 1754.22 ±647.02 1144.57 ±527.56* 0.0263 
CD11b
-
 CD27
+
 
% 0.30 ±0.84 0.30 ±1.42 0.8119 
MFI CD27 2117.00 ±0.00 1862.00 ±378.00 - 
MFI CD11b 186.00 ±0.00 191.00 ±7.00 - 
CD11b
+
 CD27
+
 
% 0.98 ±1.39 12.19 ±26.69 0.2097 
MFI CD27 1634.67 ±573.95 1244.48 ±250.44 0.1797 
MFI CD11b 2556.00 ±1272.61 3322.10 ±1436.54 0.2938 
CD11b
+
 CD27
-
 
% 95.03 ±6.61 82.31 ±31.02 0.4121 
MFI CD27 4.39 ±8.79 96.61 ±194.48* 0.0237 
MFI CD11b 2683.11 ±576.38 2682.09 ±1005.39 1.0000 
CD11b
-
 CD27
-
 
% 3.69 ±6.63 1.19 ±2.07 0.1598 
MFI CD27 1.94 ±4.76 85.36 ±120.55** 0.0058 
MFI CD11b 176.66 ±65.75 211.79 ±73.88 0.2183 
Values represent mean ±SE (HC n=25; TB n=9). Not significant data (Mann Whitney test). 
 
 
Activating KIR: KIR2DS1 
 According to the length of the cytoplasmatic tail, KIR can be inhibitory or 
activating. The sort tail (S) has activation function. Here, once again methods and data 
analysis were based on David et al. (115) (Figure 16-1). CD158a/h correspond to 
KIR2DL1 (CD158a) – inhibitory receptor – and KIR2DS1 (CD158h) and the expression 
of these two KIR was analysed in TB and HC (Figure 16-2). 
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 The percentage of NK cells expressing KIR2DS1 is significantly higher in TB 
patients and when the compare the mean of fluorescence intensity of the two markers 
that defines this population there’s no differences to report.  
 
Figure 16 – 1A, 1B – Representative dot plots of NK cells expressing KIR2DS1 in TB and HC, 
respectively.1C – Analysis of NK cell KIR2DS1
+
 in peripheral blood of TB (gray, n=28) and HC (white, 
n=11). 1D – Mean fluorescence intensity for CD158a/h and 8C11 in NK cell KIR2DS1
+
 of TB and HC. 2A – 
Representative histogram of CD158a/h expression in NK cells from TB (red) and HC (blue). 2B – Analysis 
of CD158a/h expression on NK cell in peripheral blood of TB (gray, n=27) and HC (white, n=9). 2C – Mean 
fluorescence intensity of CD158a/h in NK cells of TB and HC. Gated lymphocytes were used in analysis. 
**p<0.01 compared to HC (Mann Whitney test). 
 
 KIR2DS1+ cells are greatly differentiated: high levels of CD16 and 
predominance of CD11b+CD27- subset (Table 16) as expected for KIR+ cells. There are 
significant reduction in two CD27/CD11b subsets in TB patients (CD11b-CD27+ and 
CD11b+CD27+), however the absolute numbers are similar. 
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Table 16 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for KIR2DS1
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 85.96 ±22.79 80.47 ±23.34 0.3572 
MFI CD16 1656.55 ±762.76 1332.07 ±671.50 0.2466 
CD11b
-
 CD27
+
 
% 0.25 ±0.51 0.06 ±0.14* 0.0301 
MFI CD27 3239.00 ±2845.02 2389.83 ±1466.43 0.8357 
MFI CD11b 193.31 ±157.31 264.83 ±203.31 0.8357 
CD11b
+
 CD27
+
 
% 0.69 ±0.56 0.33 ±0.44* 0.0451 
MFI CD27 2023.00 ±1314.96 2946.27 ±1530.93 0.1272 
MFI CD11b 2554.20 ±1632.15 1957.33 ±922.13 0.4212 
CD11b
+
 CD27
-
 
% 93.13 ±3.53 89.84 ±18.95 0.1978 
MFI CD27 74.66 ±40.83 60.68 ±38.50 0.2955 
MFI CD11b 2303.36 ±871.68 2475.15 ±954.72 0.7968 
CD11b
-
 CD27
-
 
% 5.94 ±3.24 6.19 ±7.88 0.3506 
MFI CD27 60.74 ±65.62 60.01 ±61.60 0.9230 
MFI CD11b 326.09 ±81.16 368.89 ±85.44 0.2337 
Values represent mean ±SE (HC n=28; TB n=11). *p<0.05 compared to HC (Mann Whitney test). 
 
The co-expressing cells for KIR2DS1 and KIR2DL1 (CD158a/h+) are 
represented in histogram on Figure 13-2. Values are significantly different from values 
for isolated KIR2DS1. Levels of maturity are about the same as those observed for 
KIR2DS1+ cells (Table 16).  
These two KIR belongs to the same group, based on their structural 
characteristics (KIR2D type I) but belong to different haplotypes (KIR2DS1 – haplotype 
B and KIR2DL1 – haplotype A) (116). 
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Table 17 – Percentage of cells CD16
+
 and in each CD27/CD11b subset for CD158a/h
+
 cells in TB and HC. 
Means of fluorescence intensity for CD16, CD27 and CD11b. 
  HC TB P 
CD16
+
 
% 93.41 ±5.77 82.43 ±18.77 0.1119 
MFI CD16 1537.78 ±537.21 1123.30 ±536.24 0.0650 
CD11b
-
 CD27
+
 
% 0.16 ±0.21 0.07 ±0.13 0.1662 
MFI CD27 2797.50 ±2611.08 1272.00 ±1744.33 0.1806 
MFI CD11b 97.37 ±64.81 183.73 ±73.99 0.0727 
CD11b
+
 CD27
+
 
% 3.99 ±4.46 21.73 ±30.40 0.1342 
MFI CD27 987.22 ±548.25 766.69 ±286.87 0.3551 
MFI CD11b 1938.67 ±656.11 2151.81 ±838.34 0.7771 
CD11b
+
 CD27
-
 
% 93.24 ±5.72 76.35 ±29.70 0.2893 
MFI CD27 16.22 ±45.88 35.89 ±61.52 0.3935 
MFI CD11b 2212.44 ±736.53 2313.15 ±1000.11 1.000 
CD11b
-
 CD27
-
 
% 2.61 ±2.90 1.86 ±2.77 0.3509 
MFI CD27 18.99 ±27.06 37.56 ±61.53 0.7919 
MFI CD11b 101.40 ±31.32 116.66 ±73.22 0.3784 
Values represent mean ±SE (HC n=27; TB n=9). Not significant data (Mann Whitney test). 
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CONCLUSION 
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 Pulmonary tuberculosis still remains one of the greatest public health problems. 
In some research NK cells’ importance have already studied, however the human NK 
cell phenotype in this pathology and in healthy contacts remains unclear. Several 
works have this NK cell characterization in animal models, and a few in human, but a 
wide research was needed. 
Taken together the presented results for these NK cell characterization in both 
TB patients and healthy contacts, NK cells from TB patients suggest a higher 
maturation, a higher activation and also higher levels of cytokine (IFN-γ) production. 
 From the beginning, TB patients present a moderate lymphopenia (p<0,05) with 
a decreasing trend in all lymphocyte subsets. The exception was observed in B cells 
that tend to be increased and in T CD8+ cells that were significantly decreased 
(p<0,05). 
 As it was observed when lymphocyte subsets were evaluated and confirmed 
with other labeling, NK cells (CD3-CD56+) in TB patients tend to decrease, however, 
when CD3-NKp46+ NK cells were counted, it was observed a partial increase in TB 
patients. NKp46 was recently referred as better marker than CD56 for NK cells, 
however it was not found a correlation between this to markers nor in TB patients and 
in HC. 
 The classic markers for NK cells are CD56 and CD16. It is defined four subsets 
according the level of expression of these two markers in CD3- cells. Results suggest a 
higher percentage of NK cells in more mature stages in TB patients. The expression of 
CD27/CD11b in NK cells surface also define developmental subsets but presented 
data do not demonstrate differences between two groups.  
CD57 is present in more mature NK cells, the expression of this marker were 
greatly increased in TB patients NK cells (p<0.0005). Despite CD27/CD11b, the higher 
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percentage of CD57+ cells and also the CD56/CD16 expression profile suggest a 
higher percentage of more mature NK cells in peripheral blood of TB patients. 
 It was observed a great increase in intracellular IFN-γ in total NK cells from TB 
patients (p<0.01). These increased values were also observed in NKp30, NKp44 and 
NKp80 positive subsets (p<0.05). 
 The co-expression of CD94 and NKG2D was also evaluated and a significant 
increase was observed in double positive subset (p<0.05) in TB patients. The meaning 
of these observations remains unclear. 
 Other NCRs and NKp80 (co-receptor) expression was increased (NKp44: 
p<0.05; NKp80: p<0.01; NKp30: n.s.). As referred above, it was observed an increase 
in intracellular IFN-γ+ in all NK cells expressing these receptors and co-receptor. 
 Killer Immunoglobulin-like receptors expression was evaluated. Data 
demonstrate that three inhibitory KIRs (KIR2DL2, KIR2DL1 and KIR3DL1) tend to 
decrease, KIR2DL2/DL3 tend to increase and activating KIR2DS1 was significantly 
increased (p<0.005). 
 Despite the importance of the presented data, further research is needed. A 
general phenotyping of NK cells was performed, giving some highlights about the role 
of these cells in TB, opening new doors for the future work. KIR genotyping have to be 
done for the TB patients and HC for correlations to the phenotype results. Also the 
gene expression of KIR genes, cytokines, chemokines, as well as the SNP screening 
for NK cells receptors. Once NK cells crosstalk with other immune cells, the effect of 
NK cells on other cells (e.g. dendritic cells and monocytes) should be studied. 
Functional activation and inhibition tests should be performed to evaluate NK cells role 
in immune response against pulmonary TB. 
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 Expansion and manipulation of NK cells for immunotherapy in infectious 
diseases is a promising field that remains to be explored. 
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